July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
Survey of TREATment for Diabetic Macular Edema (STREAT-DME) Study: Results by year from real world data in Japan
Author Affiliations & Notes
  • TAKUYA UTSUMI
    Department of Ophthalmology, Tokyo Medical University Hachioji Medical Center, Tokyo, Hachioji, Japan
  • Masahiko Shimura
    Department of Ophthalmology, Tokyo Medical University Hachioji Medical Center, Tokyo, Hachioji, Japan
  • Shigehiko Kitano
    Department of Ophthalmology, Tokyo Women's Medical University, Tokyo, Japan
  • Taiji Sakamoto
    Department of Ophthalmology, Kagoshima University, Kagoshima, Japan
  • Footnotes
    Commercial Relationships   TAKUYA UTSUMI, None; Masahiko Shimura, Alcon Pharma (F), Bayer HealthCare (F), Wakamoto Pharmaceutical (C); Shigehiko Kitano, Novartis Pharma (F); Taiji Sakamoto, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 1057. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      TAKUYA UTSUMI, Masahiko Shimura, Shigehiko Kitano, Taiji Sakamoto; Survey of TREATment for Diabetic Macular Edema (STREAT-DME) Study: Results by year from real world data in Japan. Invest. Ophthalmol. Vis. Sci. 2018;59(9):1057.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : In the treatment of Diabetic Macular Edema (DME), a multicenter retrospective registration survey of a 2-year treatment course in clinical practice has been conducted. Here, we report about a statistical analysis in terms of Visual Acuity (VA) from the viewpoint of comparing the year of starting interventional treatment.

Methods : Based on clinical records, 1171 treatment näive DME eyes which had been started interventional treatment from 2010 to 2014 for 2 years at 18 domestic facilities were registered. The VA, Central Retinal Thickness (CRT) and the required number of each intervention (anti-VEGF drugs, corticosteroid, macula photocoagulation or vitrectomy) during the clinical course were extracted.

Results : Interventional treatment for 247 eyes was started before 2011, 219 eyes in 2012, 331 eyes in 2013, 313 eyes in 2014. The improvement of VA was -0.058±0.364 log MAR, -0.037±0.343 log MAR, -0.043±0.376 log MAR, -0.082±0.352 log MAR. The number of eye treated by anti-VEGF drugs was 111 (44.9%), 145 (66.2%), 199 (60.1%), 248 (79.2%).

Conclusions : From this real world data, the newer the year of starting interventional treatment, the better improvement of VA was obtained after a 2-year treatment course for DME in clinical practice. And the proportion of eyes treated by anti-VEGF injection has increased from year to year.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×